Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?

Clin Oral Implants Res. 2011 Jan;22(1):100-5. doi: 10.1111/j.1600-0501.2010.01965.x. Epub 2010 Oct 13.

Abstract

Purpose: the purpose of this retrospective study was to examine the possibility of utilizing serum C-terminal telopeptide cross-link of type I collagen (s-CTX) and serum osteocalcin (s-OC) as risk markers for oral bisphosphonate-related osteonecrosis of the jaws (BRONJ).

Patients and methods: the s-CTX values and the s-OC values were measured from 23 patients (one male, 22 females) diagnosed with BRONJ using clinical and radiographic examinations. The two biochemical markers were evaluated during a regular checkup for osteoporosis management. For the control group of s-CTX study, s-CTX values were obtained from 61 independently recruited postmenopausal women who have been on bisphosphonate therapy for >6 months. The s-CTX values of the ONJ group and the control group were compared. Because of retrospective nature of this study, the control group for s-OC study could not be established. A single sample t-test was performed for the s-OC value from the ONJ group.

Result: twenty-three ONJ patients had taken alendronate for osteoporosis treatment, and the s-CTX testing results were low levels of 10-192 pg/ml (mean: 93.2 ± 49.4 pg/ml). Mean of s-CTX of the control (n=61) was 125 ± 85.7 pg/ml. The duration of BP therapy ranged between 1 and 10 years (4.82 ± 2.6). The s-OC level was estimated between 0.2 and 5.4 ng/ml (1.91 ± 1.51 ng/ml). The mean s-CTX value of the control group was higher but without significance (P=0.12). The s-OC values of the ONJ group were significantly lower than the lowest value of the reference range (P<0.001).

Conclusion: as a result of the s-CTX and s-OC testings at the diagnosis of BRONJ, the values of the two markers were decreased. The decrease of the s-OC values implies a problem during the bone-formation process. Therefore, we can assume that in this patient group, invasive dental surgery contributes to an increase in the risk of BRONJ incidence. This result may imply that, during bisphosphonate therapy, simultaneous consideration of s-CTX showing inhibition of bone resorption and s-OC indicating the degree of bone formation might be a set of risk markers assessing risk prediction for BRONJ before invasive dental surgery.

Publication types

  • Validation Study

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Alendronate / administration & dosage
  • Alendronate / adverse effects*
  • Biomarkers / blood*
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / adverse effects*
  • Collagen Type I / blood
  • Contraindications
  • Female
  • Humans
  • Jaw Diseases / blood
  • Jaw Diseases / chemically induced*
  • Male
  • Middle Aged
  • Osteocalcin / blood
  • Osteonecrosis / blood
  • Osteonecrosis / chemically induced*
  • Osteoporosis / prevention & control
  • Peptides / blood
  • Retrospective Studies
  • Risk Assessment
  • Statistics, Nonparametric
  • Surgery, Oral

Substances

  • Biomarkers
  • Bone Density Conservation Agents
  • Collagen Type I
  • Peptides
  • collagen type I trimeric cross-linked peptide
  • Osteocalcin
  • Alendronate